| Ytd | -54.65% | |
| 1y | -60.61% |
| Open | 0.92 | Prev Close | 0.93 | Low | 0.88 | High | 0.93 | Mkt Cap | 43.38M |
| Vol | 140.02K | Avg Vol | 323.79K | EPS | -0.87 | P/E | N/A | Forward P/E | N/A |
| Beta | -0.70 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 1.04 | 200-d Avg | 1.77 | 1yr Est | 0.00 |
FLNA News
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NE
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the anal
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Th
Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and an
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the anal
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana The
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana The
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cassava Sciences (NASDAQ: FLNA - Get Free Re
Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufila